Premium
Zuranolone leads to rapid improvement in women with postpartum depression
Publication year - 2021
Publication title -
the brown university psychopharmacology update
Language(s) - English
Resource type - Journals
eISSN - 1556-7532
pISSN - 1068-5308
DOI - 10.1002/pu.30776
Subject(s) - depression (economics) , postpartum depression , psychopharmacology , medicine , psychiatry , antidepressant , placebo , depressive symptoms , alternative medicine , psychology , anxiety , pregnancy , genetics , economics , biology , macroeconomics , pathology
The investigational drug zuranolone improved depressive symptoms relative to placebo for women with postpartum depression, a Phase 3 trial has found. Improvement was seen by day 3 of treatment in the 2‐week trial, and the antidepressant effects persisted through day 45 of follow‐up, the researchers reported. Study results were published online June 30, 2021, in JAMA Psychiatry .
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom